Literature DB >> 20488766

Vertebral osteolysis originating from subchondral cyst end plate defects in transforaminal lumbar interbody fusion using rhBMP-2. Report of two cases.

Sarah Balseiro1, Eric W Nottmeier.   

Abstract

BACKGROUND CONTEXT: Vertebral osteolysis has been reported as a complication of off-label recombinant human bone morphogenetic protein-2 (rhBMP-2) use in transforaminal lumbar interbody fusion (TLIF). It has been postulated that end plate violation during disc space preparation, rhBMP-2 overdosing, or a combination thereof can contribute to the development of vertebral osteolysis when rhBMP-2 is used in the lumbar interspace.
PURPOSE: To present two cases of vertebral osteolysis that occurred after TLIF in which rhBMP-2 was used. In each case, the osteolysis originated from subchondral cysts that were present on preoperative computed tomographic (CT) scans. STUDY
DESIGN: Case report.
METHODS: Two patients underwent instrumented TLIF using INFUSE (Medtronic, Inc., Littleton, MA, USA) on an absorbable collagen sponge carrier. In each patient, approximately 4 mg of rhBMP-2 was placed anteriorly in the disc space with 0.1 mg of rhBMP-2 being placed inside a polyetheretherketone interbody cage. Morcellized allograft bone mixed with demineralized bone matrix was also placed in the disc space and cage. The remaining rhBMP-2 was placed posterolaterally on the contralateral side. Each patient presented with worsening back pain approximately 3 to 4 months postoperatively and CT scans revealed osteolysis affecting the L4 and L5 vertebral bodies. The osteolysis appeared to originate from preoperative vertebral defects caused by subchondral cysts.
RESULTS: One patient underwent removal of the interbody cage at the L4-L5 level and revision of the fusion with iliac crest autograft. At 15-month follow-up, he had no complaints of back pain, and CT scanning revealed solid fusion across the L4-L5 disc space. The other patient was offered revision of his fusion but declined any further surgery. At 2-year follow-up, that patient had persistent back pain but still declined any further surgery. A CT scan revealed unchanged osteolysis at the L4 and L5 levels.
CONCLUSIONS: It has been proposed that rhBMP-2-induced vertebral osteolysis occurring in TLIF procedures may be secondary to end plate violation during disc preparation or overdosing of rhBMP-2. Although overdosing may have also contributed to vertebral osteolysis in our two cases, the end plate violation from subchondral cyst formation that was present on preoperative CT scans seemed to be the origin of the osteolysis suggesting that the presence of preoperative subchondral cysts may be an additional risk factor for development of osteolysis in these patients. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488766     DOI: 10.1016/j.spinee.2010.04.013

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  12 in total

1.  Bone morphogenetic protein and orthopaedic surgery: can we legitimate its off-label use?

Authors:  Aurélien Courvoisier; Frederic Sailhan; Olivier Laffenêtre; Laurent Obert
Journal:  Int Orthop       Date:  2014-09-30       Impact factor: 3.075

2.  Growth factor sequestration and enzyme-mediated release from genipin-crosslinked gelatin microspheres.

Authors:  Paul A Turner; Jeffrey S Thiele; Jan P Stegemann
Journal:  J Biomater Sci Polym Ed       Date:  2017-07-20       Impact factor: 3.517

Review 3.  A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.

Authors:  Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part B Rev       Date:  2016-04-19       Impact factor: 6.389

4.  BMP2-induced inflammation can be suppressed by the osteoinductive growth factor NELL-1.

Authors:  Jia Shen; Aaron W James; Janette N Zara; Greg Asatrian; Kevork Khadarian; James B Zhang; Stephanie Ho; Hyun Ju Kim; Kang Ting; Chia Soo
Journal:  Tissue Eng Part A       Date:  2013-07-17       Impact factor: 3.845

5.  Pros, cons, and costs of INFUSE in spinal surgery.

Authors:  Nancy E Epstein
Journal:  Surg Neurol Int       Date:  2011-01-24

6.  Costs and frequency of "off-label" use of INFUSE for spinal fusions at one institution in 2010.

Authors:  Nancy E Epstein; Garry S Schwall
Journal:  Surg Neurol Int       Date:  2011-08-17

7.  Recombinant human bone morphogenetic protein 2 labeled use in spinal surgery and sexual dysfunction.

Authors:  Marija Rakovac; Ivan Bojanic; Tomislav Smoljanovic
Journal:  Surg Neurol Int       Date:  2011-04-28

8.  Dexamethasone enhances osteogenic differentiation of bone marrow- and muscle-derived stromal cells and augments ectopic bone formation induced by bone morphogenetic protein-2.

Authors:  Masato Yuasa; Tsuyoshi Yamada; Takashi Taniyama; Tomokazu Masaoka; Wei Xuetao; Toshitaka Yoshii; Masaki Horie; Hiroaki Yasuda; Toshimasa Uemura; Atsushi Okawa; Shinichi Sotome
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

9.  NELL-1 in the treatment of osteoporotic bone loss.

Authors:  Aaron W James; Jia Shen; Xinli Zhang; Greg Asatrian; Raghav Goyal; Jin H Kwak; Lin Jiang; Benjamin Bengs; Cymbeline T Culiat; A Simon Turner; Howard B Seim Iii; Benjamin M Wu; Karen Lyons; John S Adams; Kang Ting; Chia Soo
Journal:  Nat Commun       Date:  2015-06-17       Impact factor: 14.919

Review 10.  The controversy surrounding bone morphogenetic proteins in the spine: a review of current research.

Authors:  Joshua W Hustedt; Daniel J Blizzard
Journal:  Yale J Biol Med       Date:  2014-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.